Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
US HARMONY in DIVERSITY
NCT06783621Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of botulinum toxin type A and Neobella in facial contouring (2 cohorts), sponsored by AbbVie Inc. Primary endpoint: FACE-Q Satisfaction with Facial Appearance Scale at 284 days. Started Jan 2025; status: completed.
02
Drugs
botulinum toxin type ANeobella
03
Conditions
facial contouring
Beyond the preview
Go deeper on NCT06783621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783621.